Shortage Within A Shortage: Baxter Adjusts Allocation Of I.V. Products As Shortage Drives Demand
This article was originally published in The Pink Sheet Daily
Executive Summary
Baxter cancels all old orders of I.V. solution products as shortage strikes up demand; company maintains initial increased demand sparked shortage, despite FDA manufacturing warning letters.
You may also be interested in...
Code Cart Crisis: Anatomy Of An Emergency Drug Shortage
How FDA, health care providers, and Pfizer and other drug makers are responding to a shortage of emergency medicines from the fragile, overstressed US sterile injectables sector.
Contamination and Raw Material Testing Issues Raised in FDA Warning Letters
FDA investigators are continuing to find contamination problems and inadequate testing, according to 20 warning letters issued in the first half of 2013, as well as a troubling trend of repeat observations at Baxter, Hospira and Apotex. Observers say to expect more sterility concerns in future warning letters, particularly involving mold, as FDA ramps up GMP enforcement at compounding pharmacies.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.